September/October

The pharmaceutical industry is facing increased scrutiny from lawmakers about the appropriateness of high drug prices.

The specialty pharmacy marketplace has quickly become the primary dispenser of most therapies for orphan conditions.

The growing cost of specialty products places greater importance on the support that patients receive.

Properly managing reimbursement is critical to managing costs and outcomes in an evolving payment environment.

USP outlines new quality-of-practice standards for handling hazardous drugs that promote the safety of patients and health

Value-based contracts among pharmaceutical manufacturers and payers have not achieved the success levels necessary to drive significant systemic change.

The introduction of preferred formulary status for lower-cost generics was the first example of value-based pharmacy benefit management.

Pharmacies that do not differentiate themselves and fail to provide must-have services will lose out to their competitors.

State regulators and legislatures are considering new requirements for controlled substance prescribing and reporting.